FTC-L’Oreal Settlement Should Reverberate Across Industry – Attorneys
This article was originally published in The Rose Sheet
Executive Summary
The recent action against L’Oreal sends a signal to industry that FTC is paying attention to their claims. In an interview with “The Rose Sheet,” attorneys from Edwards Wildman Palmer discuss the case’s implications and whether it heralds a new FTC focus on cosmetics.
You may also be interested in...
NuGene Growing Its Stem-Cell Cosmeceuticals Biz; Regulatory Risks Noted
NuGene's sales have soared with expanded distribution, but increased regulation continues to be a risk to its human stem-cell-based cosmeceuticals business, the firm notes. Skin and hair-care line extensions will launch later this year, and the company is considering developing an in-house sales force.
Audio Feature: FDA Monitoring Cosmetic Claims, But Litigation Remains Biggest Threat
Attorney Steven Shapiro, a partner at Ullman, Shapiro & Ullman, LLP, offers perspective on what he considers some of the biggest challenges cosmetics companies face in the current regulatory and legal landscape, specifically when it comes to crafting claims. Story features audio clips from the attorney’s interview with “The Rose Sheet.”
Are Beauty Ads Held To Unique Standards? NARB Ruling Spurs Debate
At the National Advertising Division’s Annual Conference, NAD staffers, FTC officials and attorneys discussed whether beauty ads are regulated differently from advertising in other industries. L’Oreal’s successful appeal of a recent NAD decision regarding the use of lash inserts in Maybelline mascara ads could set a new and questionable precedent, according to NAD Director Andrea Levine.